1,5-anhydroglucitol Blood Test More Accurate than HbA1c and Glucose for Predicting Mortality COVID-19 Patients with and without Diabetes

This week, Precision Diabetes, Inc. presented data demonstrating that the 1,5-anhydroglucitol blood test (GlycoMark®) is more accurate than commonly used diabetes tests in predicting mortality in hospitalized COVID-19 patients with and without diabetes. The study, “1,5-anhydroglucitol is an Independent Predictor of Mortality in Patients with COVID-19,” was presented at the American Heart Association (AHA) 2021 Scientific Sessions conference.

The study, conducted at Sinai Hospital in Baltimore, Md., showed that the GlycoMark® test had 76% mortality accuracy (AUC) compared to the accuracy for HbA1c and fasting glucose of 51% and 60%, respectively. The accuracy of GlycoMark was higher in patients without diabetes (79%) than in patients with diabetes (73%). An algorithm, which included age, BMI, and GlycoMark had an accuracy for prediction of mortality of 89%.

“We were pleased to find that the GlycoMark test identified mortality with high accuracy in COVID-19 patients,” says Paul Gurbel, MD, a cardiologist at the The LifeBridge Health Cardiovascular Institute and lead investigator of the trial. “GlycoMark may have utility in triaging COVID-19 patients in the hospital setting at higher risk of severity and mortality. This may be especially important in COVID-19 non-diabetic patients who may develop new-onset diabetes, which brings higher risks of severe disease and death.”

This study follows a previously reported study presented as a late-breaking abstract at the 2021 American Diabetes Association (ADA) Scientific Sessions, which showed that GlycoMark was an effective marker of stress hyperglycemia and severity in COVID-19 patients, particularly in patients without diabetes. The study was conducted at Hospital Universitario Cruces in Bilbao, Spain.

You may also like

  • AI-Powered Mobile Retina Tracker Screens for Diabetic Eye Disease with 99% Accuracy

    A novel AI-powered retina tracker can analyze retinal images with near-perfect accuracy in under one second, according to a study being presented Monday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif. The researchers say the findings offer hope for sight-saving screenings for diabetic retinopathy and other eye diseases that are fast, affordable,…

  • Should  SGLT2 Inhibitors Be Stopped Before Emergency Surgery?

    A new study entitled “Postoperative Outcomes Among Sodium-Glucose Cotransporter 2 Inhibitor Users” published in JAMA Surgery calls into question the current guidelines advising doctors to pause a widely used class of diabetes drugs—sodium-glucose cotransporter 2 inhibitors (SGLT2i) — before surgery. The findings suggest the risk of developing postoperative euglycemic ketoacidosis (eKA), a serious and potentially…